|Chemical and physical data|
|Molar mass||413.54 g/mol g·mol−1|
|3D model (JSmol)|
Lupitidine (INN; lupitidine hydrochloride (USAN); development code SKF-93479) is a long-acting H2 receptor antagonist developed by Smith, Kline & French and described as an antiulcerogenic that was never marketed. It was shown to inhibit nocturnal gastric acid secretion and, in experiments on rodents, produced diffuse neuroendocrine cell hyperplasia and an increase in multifocal glandular hyperplasia due to hypergastrinemia resulting from the pharmacological suppression of gastric acid secretion.
- Franzén, L; Ghassemifar, R; Malcherek, P (July 1991). "Experimental Mast Cell Activation Improves Connective Tissue Repair in the Perforated Rat Mesentery". Agents and Actions. 33 (3–4): 371–7. doi:10.1007/bf01986588. PMID 1683107.
- J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 745–. ISBN 978-1-4757-2085-3.
- Dammann, H.G.; Muller, P.; Simon, B. (January 1982). "Inhibition of Nocturnal Acid Secretion by H2-Receptor-Antagonist SKF 93479". The Lancet. 319 (8265): 224. doi:10.1016/S0140-6736(82)90788-7.
- Betton, GR; Dormer, CS; Wells, T; Pert, P; Price, CA; Buckley, P (1 February 1988). "Gastric ECL-Cell Hyperplasia and Carcinoids in Rodents Following Chronic Administration of H2-antagonists SK&F 93479 and Oxmetidine and Omeprazole". Toxicologic Pathology. 16 (2): 288–298. doi:10.1177/019262338801600222. PMID 2903544.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|